“As API suppliers, we've been a little bit in the middle,” Gomes says. “We see what is going on with our customers who will be generic or branded drug manufacturers, but we also see what is going on within the earliest phase of the supply chain.This technique has become explored for both of those little- and huge-molecule APIs and it has show